Literature DB >> 14563345

Preconditioning and metabolic anti-ischaemic agents.

Lionel H Opie1.   

Abstract

Preconditioning a powerful protective mechanism, is the response to transient ischemia and reperfusion. However, the best way to achieve total protection is to avoid ischemia altogether. Therefore prevention of ischemia and protection by preconditioning are differently mediated so that anti-ischemic agents may not precondition, whereas paradoxically pro-ischemic agents may precondition. Metabolically active agents such as glucose-insulin-potassium, trimetazidine and ranolazine that protect from ischemia, increase glucose metabolism relative to that of fatty acids. By promoting glycolysis they tend to close the ATP-dependent potassium channels that help to mediate preconditioning. By lessening the oxygen-wasting effects of fatty acids, they are mitochondrial protective and oxygen-sparing. These qualities should help in the therapy of myocardial ischemia and also heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563345     DOI: 10.1016/s0195-668x(03)00439-1

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

1.  Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression.

Authors:  Sheik Wisel; Mahmood Khan; M Lakshmi Kuppusamy; I Krishna Mohan; Simi M Chacko; Brian K Rivera; Benjamin C Sun; Kálmán Hideg; Periannan Kuppusamy
Journal:  J Pharmacol Exp Ther       Date:  2009-02-13       Impact factor: 4.030

2.  Acute hyperglycemia abolishes ischemic preconditioning by inhibiting Akt phosphorylation: normalizing blood glucose before ischemia restores ischemic preconditioning.

Authors:  Zequan Yang; Yikui Tian; Yuan Liu; Sara Hennessy; Irving L Kron; Brent A French
Journal:  Oxid Med Cell Longev       Date:  2013-11-25       Impact factor: 6.543

3.  Role of Trimetazidine in Ischemic Preconditioning in Patients With Symptomatic Coronary Artery Disease.

Authors:  Leandro M A Costa; Paulo C Rezende; Rosa M R Garcia; Augusto H Uchida; Luis Fernando B C Seguro; Thiago L Scudeler; Edimar A Bocchi; Jose E Krieger; Whady Hueb; José Antonio F Ramires; Roberto Kalil Filho
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.